Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-18

Clinical Trial Update: Subject Satisfaction With AbobutulinumtoxinA Treatment [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing patient satisfaction with AbobutulinumtoxinA for glabellar frown lines has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AbobutulinumtoxinA

Snippet

Sponsor: Galderma R&D | Conditions: Glabellar Frown Lines | Phase 4 | Status: COMPLETED | Results posted: 2020-03-18